tm logo
OXABACT
Dead/Abandoned
ABANDONED - NO STATEMENT OF USE FILED

no statement of use filed

on 01 Mar 2021

Last Applicant/ Owned by

Regeringsgatan 111

Stockholm

SE

11139

Serial Number

88576525 filed on 13th Aug 2019

Registration Number

N/A

Correspondent Address

Donna J. Bunton

NIXON & VANDERHYE P.C.

901 NORTH GLEBE ROAD, 11TH FLOOR

ARLINGTON VA 22203

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

OXABACT

Pharmaceutical preparations for use in urology, gastroenterology, oncology and immunology and for the treatment of diabetes, infectious diseases, inflammation and metabolic diseases, all for therapeutic use; pharmaceutical preparations for the treatment of kidney stones; pharmaceutical products for the treatment and prevention of kidney diseases in patients with hyperoxaluria

Classification Information


Class [005]
Pharmaceutical Products


Pharmaceutical preparations for use in urology, gastroenterology, oncology and immunology and for the treatment of diabetes, infectious diseases, inflammation and metabolic diseases, all for therapeutic use; pharmaceutical preparations for the treatment of kidney stones; pharmaceutical products for the treatment and prevention of kidney diseases in patients with hyperoxaluria

Mark Details


Serial Number

No 88576525

Mark Type

No Service/Collective Mark

Attorney Docket Number

No DJB/2739-179

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
01st Mar 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
01st Mar 2021ABANDONMENT - NO USE STATEMENT FILED
28th Jul 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
02th Jun 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02th Jun 2020PUBLISHED FOR OPPOSITION
13th May 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
28th Apr 2020ASSIGNED TO LIE
21st Apr 2020APPROVED FOR PUB - PRINCIPAL REGISTER
17th Apr 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
17th Apr 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED